HIF-1α is overexpressed in leukemic cells in TP53-disrupted patients, and the selective HIF-1α inhibitor BAY87-2243 has been shown to have antitumor activity in CLL [14]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.